Evidence map›Paper›PMID 35603739›Full record

ArticleCancer medicine2023

Mesenchymal chondrosarcoma: An Australian multi-centre cohort study.

Madeleine C Strach, Peter S Grimison, Angela Hong, Richard Boyle, Paul Stalley, Rooshdiya Karim, Elizabeth A Connolly, Susie Bae, Jayesh Desai, Philip Crowe and 2 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Small round cell sarcomas.Nature reviews. Disease primers · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

Madeleine C StrachChris O'Brien Lifehouse, Sydney, New South Wales, Australia.ORCID 0000-0002-5516-2619
Peter S GrimisonChris O'Brien Lifehouse, Sydney, New South Wales, Australia.
Angela HongChris O'Brien Lifehouse, Sydney, New South Wales, Australia.
Richard BoyleChris O'Brien Lifehouse, Sydney, New South Wales, Australia.
Paul StalleyChris O'Brien Lifehouse, Sydney, New South Wales, Australia.
Rooshdiya KarimRoyal Prince Alfred Hospital, Sydney, New South Wales, Australia.
Elizabeth A ConnollyChris O'Brien Lifehouse, Sydney, New South Wales, Australia.ORCID 0000-0002-5579-3728
Susie BaePeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Jayesh DesaiPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Philip CrowePrince of Wales Hospital, Sydney, New South Wales, Australia.
Nimit SinghalCancer Centre, Royal Adelaide Hospital and Department of Medicine, University of Adelaide, Adelaide, South Australia, Australia.
Vivek A BhadriChris O'Brien Lifehouse, Sydney, New South Wales, Australia.
Royal Prince Alfred Hospital · AUChris O’Brien Lifehouse · AUThe University of Melbourne · AUThe University of Sydney · AUPrince of Wales Hospital · AURoyal Adelaide Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMesenchymal chondrosarcoma (MCS) is an ultra-rare sarcoma that follows a more aggressive course than conventional chondrosarcoma. This study evaluates prognostic factors, treatments (surgery, chemotherapy, and radiation), and outcomes in an Australian setting.

methodsWe collected demographics, clinicopathological variables, treatment characteristics, and survival status from patients with MCS registered on the national ACCORD sarcoma database. Outcomes include overall survival (OS) and progression-free survival (PFS).

resultsWe identified 22 patients with MCS between 2001-2022. Median age was 28 (range 10-59) years, 19 (86%) had localised disease at diagnosis of whom 16 had surgery (84%), 11 received radiation (58%), and 10 chemotherapy (53%). Ten (52%) developed recurrence and/or metastases on follow-up and three patients with initial metastatic disease received surgery, radiation, and chemotherapy. At a median follow-up of 50.9  (range 0.4-210) months nine patients had died. The median OS was 104.1 months (95% CI 25.8-182.3). There was improved OS for patients with localised disease who had surgical resection of the primary (p = 0.003) and those with ECOG 0-1 compared to 2-3 (p = 0.023) on univariate analysis.

conclusionsThis study demonstrates contemporary Australian treatment patterns of MCS. The role of chemotherapy for localised disease remains uncertain. Understanding treatment patterns and outcomes help support treatment decisions and design of trials for novel therapeutic strategies.

Indexed as

Bone NeoplasmsChondrosarcoma, MesenchymalSarcomaSoft Tissue NeoplasmsAdolescentAdultAustraliaChildCohort StudiesHumansMiddle AgedRetrospective StudiesYoung Adultchemotherapymesenchymal chondrosarcomaprognostic factorstreatment outcome

Identifiers

PMID35603739
PMCPMC9844591
OpenAlexW4281298580

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.